120 results on '"Loberiza, Fausto R."'
Search Results
2. Veno‐occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation
3. The Impact of Obesity on Stem Cell Transplant
4. Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis
5. Practice Mapping in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia (RR ALL): The Use of Measurable Residual Disease (MRD) Assessment in Real-World U.S. Community Oncology Practice
6. Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment
7. Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin for Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
8. Veno-Occlusive Disease Characteristics in Pediatric Patients with Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin before Allogeneic Stem Cell Transplant
9. Characterization of Veno-Occlusive Disease (VOD) in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Receiving Gemtuzumab Ozogamicin (GO) before Allogeneic Stem Cell Transplant (SCT)
10. Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation
11. Promoting oral cancer examinations to medical primary care providers: a cluster randomized trial
12. Effect of Surgical Intervention on Survival of Patients With Clinical N2 Non–Small Cell Lung Cancer
13. Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience
14. Central Nervous System Complications and Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation
15. Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial
16. Mortality Patterns Among Recipients of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Myeloma in the Past Three Decades
17. Persistent Disparities in Adult Hematopoietic Cell Transplantation
18. Impact of body mass index on pulmonary complications in patients with non-Hodgkin lymphoma treated with hematopoietic stem cell transplant
19. Review of Antibody-Based Immunotherapy in the Treatment of Non-Hodgkin Lymphoma and Patterns of Use
20. Estimating the State-Level Supply of Cancer Care Providers: Preparing to Meet Workforce Needs in the Wake of Health Care Reform
21. Do Hematopoietic Cell Transplant Patients Treated on a Clinical Trial Do Better? Comparison of Characteristics and Outcomes of Patients Enrolled Versus Not Enrolled on Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial
22. Trend Analysis of Clinical Outcomes in Hodgkin Lymphoma over the Last Three Decades: Report from the Nebraska Lymphoma Study Group
23. Clinicopathologic Features, Management and Outcomes of Blastoid Variant (BV) of Mantle Cell Lymphoma (MCL): A Nebraska Lymphoma Study Group (NLSG) Experience
24. Effect of smoking on survival from non-small cell lung cancer: a retrospective Veterans’ Affairs Central Cancer Registry (VACCR) cohort analysis
25. Clinicopathologic characteristics and management trends of cutaneous invasive and in situ melanoma in older patients: a retrospective analysis of the National Cancer Data Base
26. Transplant related outcomes in patients with hematopoietic stem cell transplant withClostridium difficileassociated diarrhea
27. Clinicopathologic characteristics and management trends of cutaneous melanoma among older patients: A National Cancer Data Base (NCDB) analysis.
28. Lack of association between geographic factors and survival in hematopoietic cell transplantation.
29. Phase I/II Study of Bortezomib-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Indolent Non-Hodgkin Lymphoma, Transformed, or Mantle Cell Lymphoma
30. Insights on practice variations in the management of lymphoma and leukemia
31. Association Between Race and Survival of Patients With Non–Small-Cell Lung Cancer in the United States Veterans Affairs Population
32. Risk Factors, Therapy and Survival Outcomes of Small Cell and Large Cell Neuroendocrine Carcinoma of Urinary Bladder
33. Disparity In Clinical Outcomes Of Elderly Patients With Non-Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation According To Area Of Residence
34. Time To Insurance Approval Of Hematopoietic Stem Cell Transplantation (HSCT) Between Private and Public Payers Is Not Associated With Survival
35. Provider and Center Characteristics Of US Transplant Centers and Their Association With Survival After Allogeneic Hematopoietic Cell Transplantation (HCT) In Adults: Results From a National Survey Conducted By The Center For International Blood and Marrow Transplant Research (CIBMTR)
36. Lack Of Clinical Benefit For Routine Surveillance Imaging For Diffuse Large B-Cell Lymphoma In First Complete Remission
37. Impact of Conditioning Regimen on Outcome of 2-Year Disease-Free Survivors of Autologous Stem Cell Transplantation for Hodgkin Lymphoma
38. Does Functional Imaging Distinguish Nodular Lymphocyte-Predominant Hodgkin Lymphoma From T-Cell/Histiocyte-Rich Large B-Cell Lymphoma?
39. Effect of smoking on survival from non-small cell lung cancer.
40. Impact of rituximab on the course of low-grade follicular lymphoma.
41. Sounding the alarm on deaths from suicide and accidents after hematopoietic stem cell transplantation
42. Sarcomatoid renal cell carcinoma (SRCC): University of Nebraska Medical Center experience.
43. Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma
44. Phase I/II Trial of Ofatumumab/Lenalidamide for Patients with Relasped/Refractory B-Cell Non-Hodgkin Lymphoma: High Response Rate in Indolent Lymphoma
45. Are lymphoma survivors really at higher risk for unemployment/underemployment?
46. Advance care planning (ACP) among hematopoietic cell transplant (HCT) patients and bereaved caregivers.
47. Usual and Worst Symptom Severity and Interference With Function in Breast Cancer Survivors
48. Comparison of prognostic factors and survival outcome between gastrointestinal tract and cutaneous invasive malignant melanoma.
49. Quality of life after chemotherapy or hematopoietic cell transplant in follicular lymphoma: what's next?
50. Predictive Ability of Charlson Comorbidity Index on Outcomes From Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.